PFE 241108 32.00C (PFE241108C32000) Stock Options, News & Quotes

US OptionsDetailed Quotes

PFE241108C32000

Watchlist

0.01
0.000.00%

15min DelayClose Nov 4 16:00 ET

0.01High0.01Low

Intraday

5D
Daily

News

Pfizer (PFE.US) PARP inhibitor "talazoparib" approved for marketing.
On November 5th, the National Medical Products Administration (NMPA) official website shows that pfizer (PFE.US)'s application for marketing approval of talazoparib has been approved.
Zhitong Finance02:45 ET
Pfizer's Ponsegromab: A Promising Yet Uncertain Opportunity Influencing Hold Rating
TipRanks00:36 ET · Ratings
Monday Market Moves Sideways, Election and FOMC in Sight | Wall Street Today
Kevin Travers16:52 ET
Pfizer | 10-Q: Q3 2024 Earnings Report
SEC16:10 ET · Announcements
Why Nvidia Stock Is Less Important Than Sherwin-Williams for the Dow Jones Industrial Average
Barrons15:33 ET
Buy, Sell or Hold Pfizer Stock After Q3 Earnings Beat, Guidance Boost?
Zacks 14:15 ET

Comments

Deep Sea

26 minutes ago

$Pfizer (PFE.US)$
According to the Securities Times APP, on November 5, the official website of the National Medical Products Administration (NMPA) showed that Pfizer's talazoparib tosylate capsules (talazoparib) have been approved for marketing. Talazoparib was originally developed by BioMarin, acquired by Medivation from BioMarin in 2015, and Pfizer acquired Medivation for $14 billion in 2016, thus talazoparib belongs to Pfizer since then.

韭菜变主力

14 hours ago

$Pfizer (PFE.US)$ seize every opportunity to sell covered calls. the chart is bearish. The company massively overpaid to acquire Seagan using all cash, as a result they are pay $0.4 per share on interest expense annually. I dislike management who overpays to do M&A and/or share repurchase.

Methods

18 hours ago

$Pfizer (PFE.US)$
10M in volume with over 5B free float.. This will always be a shorts paradise.. Too many outstanding shares for such a cheap stock!🤢🤮

$Pfizer (PFE.US)$
wow... talk about a sh*show with this stock!